Immunovant, Inc. (IMVT) Balance Sheet
As of 2026-06-30 (10-Q), Immunovant, Inc. (IMVT) reported total assets of $852.5M, total liabilities of $117.1M and shareholders' equity of $735.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $797.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMVTImmunovant, Inc.Follow IMVT — free
—
Price chart with a free account
- Market cap
- 5.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2020 Mar 20 | FY2021 Mar 21 | FY2022 Mar 22 | FY2023 Mar 23 | FY2024 Mar 24 | FY2025 Mar 25 | FY2026 Mar 26 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 100.6 | 400.1 | 493.8 | 376.5 | 635.4 | 714.0 | 902.1 | 797.8 | |
| Receivables | — | 0.6 | 12.2 | 0.7 | 5.3 | 2.1 | 1.1 | 0.7 | |
| Current assets | 109.1 | 409.0 | 512.9 | 404.3 | 665.8 | 767.7 | 948.8 | 851.2 | |
| Total assets | 109.4 | 412.5 | 515.6 | 405.8 | 666.4 | 776.2 | 957.0 | 852.5 | |
| Current liabilities | 15.3 | 18.8 | 44.5 | 43.3 | 48.6 | 68.8 | 104.4 | 117.1 | |
| Total liabilities | 15.3 | 21.0 | 45.7 | 43.3 | 48.6 | 68.8 | 104.4 | 117.1 | |
| Shareholders' equity | 94.1 | 391.5 | 469.8 | 362.5 | 617.8 | 707.4 | 852.6 | 735.4 |
USD millions · SEC XBRL
Immunovant, Inc. — questions
- How much cash does Immunovant, Inc. have?
- $797.8M in cash and cash equivalents as of 2026-06-30.
- What are Immunovant, Inc.'s total assets?
- $852.5M as of 2026-06-30.
- What is Immunovant, Inc.'s shareholders' equity?
- $735.4M as of 2026-06-30.
Every figure on this page comes from Immunovant, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.